Evidence map›Paper›PMID 40847234›Full record

ReviewCancer treatment and research2025

Immunotherapy in Melanoma.

Yan Xing, Helena T Wu, Swapnil Rajurkar, Tingting Tan, Vanessa Hsu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer treatment and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yan XingCity of Hope Comprehensive Cancer Center, Duarte, CA, USA. yxing@coh.org.
Helena T WuData Science Institute, The University of Chicago, Chicago, IL, USA.
Swapnil RajurkarCity of Hope National Medical Center, Upland, CA, USA.
Tingting TanDepartment of Medical Oncology, City of Hope National Medical Center, Newport Beach, CA, USA.
Vanessa HsuCity of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This chapter explores systemic treatment strategies for cutaneous melanoma across neoadjuvant, adjuvant, and Stage IV settings. Neoadjuvant therapy aims to reduce tumor burden pre-surgery, primarily using immune checkpoint inhibitors like nivolumab plus ipilimumab, showing promising response rates. Adjuvant therapy, post-resection, leverages immunotherapy (e.g., nivolumab) and targeted therapies (e.g., dabrafenib plus trametinib) to prevent recurrence in high-risk patients, improving relapse-free survival. Stage IV systemic treatment addresses metastatic disease, employing immunotherapy (nivolumab, pembrolizumab) and targeted mitogen-activated protein kinase (MAPK) pathway inhibitors (dabrafenib plus trametinib) for BRAF-mutant cases, while BRAF wild-type patients benefit from nivolumab-relatlimab or combination therapies. Tables summarize key regimens, efficacy, and toxicities. Content aligns with clinical guidelines, with updates on emerging therapies like tumor-infiltrating lymphocytes (TIL). These approaches enhance survival and treatment-free intervals, tailored to mutation status and disease stage.

Indexed as

ImmunotherapyMelanomaSkin NeoplasmsHumansAdjuvantBRAF mutationDabrafenibImmunotherapyIpilimumabMelanomaNeoadjuvantNivolumabStage IV melanomaTargeted therapy

Identifiers

PMID40847234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.